GlassScriptPhysician profile
Michael M Han
NPI 1003443300
$2,434.33
in general payments reported to CMS, 2019-2025
13 companies · $483 in 2025
The $483 reported for 2025 was more than what a typical Ophthalmic Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $93.56 · 2022: $324 · 2023: $812 · 2024: $722 · 2025: $483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,016.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $731.57 | 2022-2024 | Clareon, Hydrus Microstent |
| Genentech USA, INC. | $279.23 | 2022-2023 | Vabysmo |
| Argenx US, INC. | $244.86 | 2024-2025 | |
| Abbvie INC. | $208.37 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $197.76 | 2025 | Ultomiris |
| Amgen INC. | $193.53 | 2024-2025 | Tepezza, Uplizna |
| Sight Sciences, INC. | $119.55 | 2025 | Omni Surgical System |
| Regeneron Healthcare Solutions, INC. | $104.76 | 2024 | Eylea Hd |
| Bausch & Lomb Americas INC. | $98.61 | 2023-2024 | Xipere, Envista Mx60 Iol, Stellaris |
| Glaukos Corporation | $88.43 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Apellis Pharmaceuticals, INC. | $27.69 | 2024 | Syfovre |
| Astellas Pharma US INC | $24.98 | 2023 | |
| Genentech, INC. | $21.43 | 2024 | Vabysmo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Han listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.